Johnson & Johnson (NYSE:JNJ) Stock Price Down 1% – Time to Sell?
by Jessica Moore · The Cerbat GemJohnson & Johnson (NYSE:JNJ – Get Free Report)’s stock price fell 1% during trading on Tuesday . The stock traded as low as $236.01 and last traded at $238.4710. 6,226,954 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 8,721,360 shares. The stock had previously closed at $240.97.
Key Headlines Impacting Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Multiple analysts are bullish ahead of JNJ’s quarterly report, keeping buy ratings and elevated price targets that support near-term upside. Johnson & Johnson: Diversified Growth, Robust Pipeline, and Attractive Risk‑Reward Support Buy Rating
- Positive Sentiment: Barron’s and other outlets argue the stock’s run into earnings can continue, citing improved momentum in MedTech and drugs versus last year. Buy Johnson & Johnson Ahead of Earnings. The Stock’s Run-Up Isn’t Over.
- Positive Sentiment: Wall Street notes (Citigroup, Guggenheim coverage) project strong price appreciation, adding institutional conviction that supports the equity. Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Guggenheim Analyst Says
- Positive Sentiment: JNJ launched its VARIPULSE Pro pulsed-field ablation system in Europe (CE Mark) — incremental MedTech growth and real‑world evidence could boost device revenue if adoption proves strong. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
- Neutral Sentiment: Investors are positioning for Q1 results; Wall Street consensus and metric estimates are published but the quarter will be the key short-term catalyst. Gear Up for Johnson & Johnson (JNJ) Q1 Earnings: Wall Street Estimates for Key Metrics
- Neutral Sentiment: Pre-earnings coverage highlights MedTech and drug growth momentum but notes results-driven volatility — outcome depends on guidance and segment detail. Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
- Negative Sentiment: Biosimilar competition and pricing pressures remain a tangible headwind for pharma margins and revenue growth; these forces could temper upside if reiterated on the earnings call. Should You Buy, Sell or Hold JNJ Stock Ahead of Q1 Earnings?
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on JNJ shares. Citigroup upped their target price on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus lifted their target price on Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Daiwa Securities Group increased their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $237.57.
Get Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
The stock’s 50 day simple moving average is $240.79 and its 200-day simple moving average is $214.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The firm has a market cap of $580.78 billion, a price-to-earnings ratio of 21.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion for the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Insider Activity
In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. J. Derek Lewis & Associates Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth $296,000. Purpose Unlimited Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $131,000. Cornerstone Planning LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,442,000. Rockefeller Capital Management L.P. increased its holdings in Johnson & Johnson by 12.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 937,751 shares of the company’s stock worth $194,068,000 after purchasing an additional 105,383 shares during the period. Finally, Bank of New Hampshire increased its position in shares of Johnson & Johnson by 4.8% in the 4th quarter. Bank of New Hampshire now owns 14,480 shares of the company’s stock valued at $2,997,000 after purchasing an additional 660 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.